Medpace - MEDP Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MEDP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEDP, but not buy additional shares or sell existing shares.
View MEDP analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued twelve-month price targets for Medpace's stock. Their MEDP share price forecasts range from $142.00 to $175.00. On average, they expect the company's share price to reach $158.50 in the next year. This suggests a possible upside of 9.0% from the stock's current price.
View analysts price targets for MEDP or view top-rated stocks among Wall Street analysts.

Medpace's stock was trading at $217.64 on January 1st, 2022. Since then, MEDP shares have decreased by 33.2% and is now trading at $145.38.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, October 24th 2022.
View our MEDP earnings forecast.

Medpace Holdings, Inc. (NASDAQ:MEDP) released its quarterly earnings data on Monday, July, 25th. The company reported $1.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.34 by $0.12. The business had revenue of $351.21 million for the quarter, compared to the consensus estimate of $344.01 million. Medpace had a trailing twelve-month return on equity of 30.56% and a net margin of 16.27%. The business's quarterly revenue was up 26.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.06 earnings per share.

Medpace updated its FY 2022 earnings guidance on Monday, August, 1st. The company provided earnings per share (EPS) guidance of $6.07-$6.36 for the period, compared to the consensus estimate of $5.82. The company issued revenue guidance of $1.41 billion-$1.44 billion, compared to the consensus revenue estimate of $1.40 billion.

268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace's stock is owned by a number of institutional and retail investors. Top institutional shareholders include State Street Corp (2.78%), Boston Trust Walden Corp (2.05%), Echo Street Capital Management LLC (2.10%), Riverbridge Partners LLC (1.43%), Riverbridge Partners LLC (1.41%) and Goldman Sachs Group Inc. (1.26%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Stephen P Ewald, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends.

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MEDP stock can currently be purchased for approximately $145.38.

Medpace (NASDAQ:MEDP) has a market capitalization of $4.51 billion and generates $1.14 billion in revenue each year. The company earns $181.85 million in net income (profit) each year or $5.76 on an earnings per share basis.

The company employs 4,500 workers across the globe.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The official website for the company is www.medpace.com. The company can be reached via phone at (513) 579-9911, via email at investor@medpace.com, or via fax at 513-579-0444.